Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported financial results for its fiscal fourth quarter and year ending September 30, 2020, revealing a total revenue of $23.6 million for Q4, down from $51.3 million in the same period in 2019. Full-year revenue also declined to $122.5 million from $205.2 million.
The company incurred a net loss of $29.3 million in Q4, attributed to decreased HCV royalties and a non-cash tax valuation charge of $18.3 million. Enanta's cash reserves increased to $419 million. Looking ahead, the R&D expenses for fiscal 2021 are expected between $145 million and $165 million.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced key participation in upcoming conferences. CEO Jay R. Luly will engage in a Fireside Chat at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 1, 2020, at 9:15 a.m. ET. Additionally, he will take part in One-on-One Meetings during the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, with a Fireside Chat available from November 25. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, funded by royalties from its collaboration with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced plans to report its financial results for the fiscal fourth quarter and year ended September 30, 2020, on November 23, 2020, after market close. A conference call will be held at 4:30 p.m. ET on the same day to discuss the results and provide updates on its business, including research and development efforts in viral infections and liver diseases. Enanta's research is funded by royalties from its collaboration with AbbVie, notably for its hepatitis C drug, Glecaprevir.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company, announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference on October 5, 2020, at 2:00 pm ET. The event will be accessible via a live webcast on Enanta’s website, with a replay available for 30 days post-presentation.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with ongoing research in RSV, NASH, HBV, and COVID-19.